57180-64-0

Upstream product

• 32580-26-0 2-(2-bromoacetamido)-5-chloro-benzophenone 
• 593-51-1 methylamine hydrochloride 
• 719-59-5 5-chloro-2-aminobenzophenone 

Downstream Products

• 59049-66-0 N-(2-Benzoyl-4-chloro-phenyl)-2-(cyanomethyl-methyl-amino)-acetamide 
• 74280-26-5 2'-Benzoyl-4'-chloro-N-(N-phthaloylglycyl)sarcosinanilide 
• 78823-08-2 2'-Benzoyl-4'-chloro-N-sarcosinanilide 
• 74280-33-4 2'-Benzoyl-4'-chloro-N-(chloroacetyl)sarcosinanilide 
• 78823-09-3 2'-Benzoyl-4'-chloro-N-(N-phthaloyl-DL-alanyl)sarcosinanilide 
• 719-59-5 5-chloro-2-aminobenzophenone 
• 74280-32-3 8-Chloro-1,5-dimethyl-10-phenyl-1H-pyrazino<2,3-b>quinolin-2(3H)-one 
• 74280-23-2 1-(2-Benzoyl-4-chlorophenyl)-4-methylpiperazine-2,5-dione 
• 74280-34-5 2'-Benzoyl-4'-chloro-N-glycylsarcosinanilide 
• 78823-10-6 2'-Benzoyl-4'-chloro-N-(DL-alanyl)sarcosinanilide 
• 78823-16-2 6-Chloro-1-methyl-3-(methylglycylamino)-4-phenyl-2(1H)-quinolone 
• 78823-15-1 8-Chloro-10-phenyl-1,3,5-trimethyl-1H-pyrazino<2,3-b>quinolin-2(3H)-one 
• 74280-28-7 8-Chloro-1,2-dihydro-6-hydroxy-2-methyl-6-phenylpyrazino<2,1-b>quinazolin-3(4H)-one 
• 78823-12-8 2-Amino-N-{[(2-benzoyl-4-chloro-phenyl)-methyl-carbamoyl]-methyl}-N-methyl-propionamide 

Relevant academic research and scientific papers

QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Disclosed herein are certain quinolinone derivatives of Formula (A) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

Cyanoalkylamino-amido benzophenones

The present invention relates to pharmacologically valuable new benzophenone derivatives having a pronounced sedative action on the central nervous system and some of which also possess muscle-relaxing and aggression-inhibiting properties. These new derivatives have the structural formula SPC1 And their addition salts, in which R1 and R2 are substituents selected from the group consisting of hydrogen, alkyl having 1-5 carbon atoms, alkenyl having 2 to 4 carbon atoms, alkinyl having 2 to 4 carbon atoms or β-bromoallyl (--CH2 --CBr = CH2) ; R3 is --CN; n is an integer selected from 1 and 2; and m is an integer selected from 1, 2 and 3, wherein the rings A and B may be substituted, ring A being substituted preferably with a halogen such as chlorine or with nitro, trifluoromethyl, methyl, methoxy or methylmercapto, preferably in the 5 position, and ring B being preferably substituted in the 2' position with chlorine or fluorine. The radical R1 preferably signify hydrogen or a methyl, ethyl or propargyl group, the radicals for R2 preferably signify hydrogen or a methyl, allyl or an n-butyl group. C compounds represented by the above structural formula may be produced by reacting a compound represented by the formula SPC2 With a compound having the formula Y -- Cm H2m -- R3, one of X and Y signifying the substituent R2 -- NH -- and the other signifying a halogen atom, preferably a bromine or chlorine atom, so as to form the above specified benzophenone derivative with the elimination of H -- Hal, R1, R2, R3, n and m being as defined above, and the rings A and B being optionally substituted as discussed above. The hydrogen halide which is eliminated is advantageously bound by the addition of an acid-binding agent, as for example, a molar excess of the amine used in the reaction or, for example, triethylamine, dimethylaniline, potassium or sodium carbonate or sodium bicarbonate. The reaction is carried out in a suitable solvent, preferably at an elevated temperature, typically the reflux temperature of the solvent used.

Benzophenone derivatives and process for their production II

The present invention relates to a pharmacologically valuable new benzophenone derivatives having a pronounced sedative action on the central nervous system and some of which also possess muscle-relaxing and aggression-inhibiting properties. These new derivatives have the structural formula EQU1 and their acid addition salts, in which R 1 and R 2 are substituents selected from the group consisting of hydrogen, saturated and unsaturated alkyl groups having 1-4 carbon atoms; R 3 is a substituent selected from the group consisting of --CN, --CONH 2, --COOCH 3, --COOC 2 H 5, --COOH, and --COOMe, where Me is a metallic cation; n is an integer selected from 1 and 2; and m is an integer selected from 1,2, and 3, and wherein the rings A and B may be substituted, ring A being substituted preferably with a halogen such as chlorine or with nitro, trifluoromethyl, methyl, methoxy or methylmercapto, preferably in the 5 position, and ring B being preferably substituted in the 2'' position with chlorine or fluorine. The radicals R 1 and R 2 preferably signify hydrogen or a methyl group, or a n-butyl group in the case of Ring B.The metal cation Me is preferably a pharmacologically acceptable metal cation, as for example sodium, potassium, calcium or ammonium.Compounds represented by the above structural formula may be produced by reacting a compound represented by the formula EQU2 with a compound having the formula Y -- C m H 2m -- R 3, one of X and Y signifying the substituent R 2 -- NH -- and the other signifying a halogen atom, preferably a bromine or chlorine atom, so as to form the above specified benzophenone derivative with the elimination of H -- Hal, R 1, R 2, R 3, n and m being as defined above, and the rings A and B being optionally substituted as discussed above. The hydrogen halide which is eliminated is advantageously bound by the addition of an acid-binding agent, as for example, a molar excess of the amine used in the reaction or, for example, triethylamine, dimethylaniline, potassium or sodium carbonate or sodium bicarbonate. The reaction is carried out in a suitable solvent, preferably at an elevated temperature, typically the reflux temperature of the solvent used.